Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENESTfreedom
NCT01784068Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2013
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 2 trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Started Mar 2013; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT01784068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01784068.